Company
Amicus Therapeutics, Inc.
Headquarters: Cranbury, NJ, United States
Founded: February 4, 2002
Employees: 496
CEO: Mr. John F. Crowley
Market Cap
$3.96 Billion
USD as of Jan. 1, 2024
Amicus Therapeutics, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Top 1-year algo backtest: +313.24%
$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Amicus Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: FOLD wb_incandescent
Stock: BMV: FOLD wb_incandescent
Stock: FSX: AM6 wb_incandescent
Key People
John Crowley (Chairman and Chief Executive Officer) Bradley Campbell (President and Chief Operating Officer) Daphne Quimi (Chief Financial Officer) David Clark (Chief People Officer)
Financials
Revenue: $91,245,000 (2018) $36,930,000 (2017)
Operating income: ($328,777,000) (2018) ($441,985,000) (2017)
Net income: ($349,089,000) (2018) ($449,121,000) (2017)
Total assets: $789,951,000 (2018) $627,024,000 (2017)
Total equity: $342,912,000 (2018) $352,850,000 (2017)